What does the ProSense® Cryoablation System cost?

Capital equipment and consumable pricing for IceCure's liquid-nitrogen cryoablation platform targeting women's health and interventional oncology.

The ProSense® Cryoablation System— the first and only medical device to receive FDA marketing authorization for the local treatment of early-stage, low-risk breast cancer with adjuvant endocrine therapy for women aged 70 and above —does not have publicly available list pricing. IceCure's official pricing excludes delivery, customs duties, and does not include installation or activation costs , but manufacturer quotes are not disclosed through GSA schedules, published price lists, or secondary markets. What is verifiable is the reimbursement landscape and the variable costs that drive total cost of ownership.

This article will be updated as MedSource accumulates hospital purchase quotes and lease data. For now, procurement leaders should reference the reimbursement ceiling, consumable spend, and competitive positioning to estimate budget impact.

What the typical range is

Specific ProSense system pricing is not publicly verifiable, which is common for Class II medical devices less than one year into U.S. market adoption. IceCure expects U.S. revenue from ProSense systems and cryoprobes to grow more than 30% in Q1 2026 versus Q1 2025 following FDA clearance in October 2025 , suggesting active procurement activity but not disclosed transaction prices.

The only hard reimbursement floor is ProSense's eligibility for reimbursement under a CPT III code covering up to $3,800 in facility fees . This cap applies to hospital outpatient and ASC settings and represents revenue—not equipment cost. Private insurance and additional Medicare CPT I coverage are anticipated but not yet established.

For comparison, other cryoablation systems operate in different price tiers: argon-based platforms (including Galil Medical or Sanarus systems) typically range $300K–$800K for capital purchase in used markets, while liquid-nitrogen platforms emphasize recurring dewar supply costs rather than fixed infrastructure (no special gas lines or high-pressure cylinder cabinets required).

What pushes price up — features, certifications, support tier

ProSense includes a single cryoprobe system with touch-screen user interface and pre-set freeze-thaw-freeze programs . Key cost drivers include:

• FDA Class II 510(k) pathway: ProSense was classified as Class II with special controls , enabling faster approval than Class III but requiring postmarket surveillance. This adds compliance cost to the manufacturer, which may be reflected in pricing.
• Transportability and facility flexibility: The system can operate in operating rooms, radiology departments, or office-based settings . Capital equipment designed for mobile deployment often costs more than fixed-room systems.
• Disposable cryoprobes and introducers: The system includes multiple cryoprobe shaft lengths and diameters , each a consumable. Probe costs are not listed but typically range $500–$1,200 per unit across the cryoablation market.
• Liquid nitrogen supply: Refillable liquid nitrogen dewars eliminate the need for gas lines, on-site technicians, or hazardous high-pressure cylinder storage . This reduces site infrastructure cost but creates ongoing logistics cost (~$30–$60 per refill, frequency dependent on procedure volume).

What pushes price down — refurbished, older generation, lease, GPO contracts

• Lease/rental rather than purchase: No manufacturer lease programs for ProSense have been announced as of May 2026. Hospital groups should inquire directly about payment plans or equipment-as-a-service models, particularly from IceCure's U.S. sales office (+1-888-902-5716). Leasing is standard for high-cost surgical devices and typically reduces effective annual cost by 30–40% vs. outright purchase.
• Used equipment: ProSense has been in clinical use since 2012 for benign fibroadenomas but received breast cancer FDA clearance only in October 2025. No established secondary or refurbished market exists yet. Watch for used-equipment dealers (e.g., Dr's Toy Store, Healthcare Technologies) to list refurbished units as deployments increase; these typically sell at 40–60% of new list price.
• GPO contracts: As of May 2026, no ProSense pricing through group purchasing organizations (e.g., Novamed, Medline) is public. IceCure may negotiate GPO agreements as adoption broadens; GPO members typically receive 10–20% discounts vs. direct pricing.

Hidden costs — install, training, calibration, consumables, service contracts

Installation and site preparation

Installation and activation charges are not included in ProSense list pricing . Typical costs: $5,000–$15,000 depending on electrical, networking, and space prep (less than argon systems due to no high-pressure gas lines).

Training and physician credentialing

The procedure for local treatment of breast cancer typically takes 20–40 minutes . Operator training is essential. IceCure should provide on-site or virtual training; budget $3,000–$8,000 per facility for initial credentialing and 2–3 surgeons/radiologists.

Consumable costs per procedure

• Disposable cryoprobes: $500–$1,200 per use (most procedures use one; complex cases may relocate probe up to 3 times, using the same probe).
• Liquid nitrogen: $50–$100 per dewar refill; facilities performing 30+ procedures/month may refill 2–4 times monthly.
• Introducer sets and accessories: $100–$300 per case.
• Estimated consumable cost per procedure: $650–$1,600 (including LN2).

Service and maintenance contracts

• Not yet published for ProSense. Comparable liquid-nitrogen systems (e.g., general cryosurgery units) typically cost 8–12% of capital value annually for a 5-year service plan.
• Estimate: $15,000–$30,000/year for a system that might cost $200K–$400K (speculative range based on competitor platforms).

Imaging requirements

• ProSense operates under ultrasound guidance. Facilities must have compatible ultrasound units or contract for portable units (~$2,000–$5,000 if new purchase).

How to negotiate — concrete tactics

1. Request direct quotes from IceCure sales: Pricing is custom. Call +1-888-902-5716 (U.S.) or email [email protected]. Provide case volume projections (procedures/month) and facility type (hospital outpatient, ASC, office). Larger volumes justify steeper discounts.

2. Bundle capital + consumables: Negotiate a per-procedure consumable fee rather than buying probes in bulk. Some OEMs offer tiered pricing at 50+, 100+, and 200+ procedure volumes annually.

3. Inquire about foundation/grant funding: Thomas Hospital's ProSense purchase was funded by the Thomas Foundation following FDA clearance . Hospital foundations, regional health boards, or cancer-focused nonprofits may underwrite acquisition in underserved areas.

4. Leverage reimbursement certainty: Cite the $3,800 facility reimbursement floor under CPT III code 0581T as a baseline for ROI negotiation. If a hospital's annual case volume is 100 procedures, revenue ceiling is $380K/year in facility fees alone—use this to justify equipment investment.

5. Request extended service agreement discounts: If the equipment is under warranty for 2 years, negotiate an inclusive 5-year service plan (parts + labor) at purchase. This locks costs.

6. Explore off-label indications: ProSense is FDA-cleared for breast cancer (ages 70+) but has approvals for benign and malignant tumors of the lung, liver, kidneys, and musculoskeletal system in Canada . Off-label use is legal; forecast additional case types to justify capital spend and negotiate higher annual commitments.

When the price feels off — red flags

• No consumable cost transparency: If a vendor won't quote per-procedure probe and LN2 costs, walk away. These are material expenses and should be contractually locked.
• Bundled reimbursement assumptions: Don't accept a vendor's claim that the $3,800 facility fee will cover your procedure cost without internal cost accounting. Reimbursement != profit margin.
• Installation surprise clauses: Confirm in writing that the quoted price includes standard electrical, networking, and space adaptation. "Additional charges for atypical sites" is a common gotcha.
• Training included ambiguity: Insist on a statement of scope: How many physicians? How many hours on-site? Who covers physician time?
• Service contract void if you use "non-authorized" consumables: Avoid exclusivity clauses that void warranty if you source third-party probes. This is rare for cryoablation but worth verifying.

Sources

FDA De Novo determination (DEN220077): Class II classification with special controls (October 2025)

FDA 510(k) clinical data submission: procedure time and technical specifications

Medscape: CPT III code 0581T reimbursement ($3,800 facility fee)

IceCure ProSense brochure (MedicalExpo PDF): pricing disclaimer and system specifications

IceCure SEC filing (April 2026): Q1 2026 revenue guidance and adoption signals

IceCure press release (February 2026): Thomas Hospital installation and foundation funding example

---

This article will be updated as hospital purchase agreements and used-equipment pricing become available. Contact MedSource or your regional group purchasing organization for aggregate quote data.